GLJ Research Reiterates Buy on Cleveland-Cliffs, Maintains $15.6 Price Target
GLJ Research analyst Gordon L. Johnson reiterates Cleveland-Cliffs (NYSE:CLF) with a Buy and maintains $15.6 price target.
Stocks · News reference
CNBC final trades: Pros picked Schwab, Cleveland-Cliffs, UnitedHealth and Incyte; shares posted mixed moves Wednesday.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
GLJ Research analyst Gordon L. Johnson reiterates Cleveland-Cliffs (NYSE:CLF) with a Buy and maintains $15.6 price target.
William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.
The Federal Reserve, under Chairman Kevin Warsh, raised the federal funds rate by a quarter point in response to persistent inflation. Historically, rate-hiking cycles have triggered an average 14% drawdown in the S&P 500 within 12 months, though stocks typically recover within a year with an average 6% return. The impact will be most severe on growth stocks and debt-dependent companies, but unless underlying earnings falter, the bull market should eventually resume.